Summary We have used the nitrosomethylurea-induced rat mammary tumour model to study the effects of parenteral administration of human recombinant tumour necrosis factor (rHu-TNF) and rat gamma interferon (IFN-y). An inbred strain of tumour bearing female Ludwig/Wistar/Olac rats were randomised to either treatment or control groups. Two independent studies showed that combined treatment with rHu-TNF and rat IFN-y induced significant tumour regression over 4 weeks (P= 0.004, P = 0.005 respectively). Treatment with either rHu-TNF or rat IFN-y given individually did not affect the overall rate of tumour growth (P=0.157 and 0.40 respectively) although an initial reduction in tumour size was observed during the first few days after injection. Measurement of circulating oestradiol levels in groups in which maximum tumour regression was observed showed no statistically significant difference when compared to the control group. Similarly, measurement of oestrogen receptor content showed no statistically significant difference between rHu-TNF-y or rat-IFN-y treatment or combined treatment of rHu-TNF and IFN-y with the control group. We conclude from these observations that combined therapy with rHu-TNF and rat IFN-y may prove to be useful new forms of treatment for human breast cancer.
Various forms of therapy are available for patients with advanced breast disease. These can lead to a period of remission, but in most cases do not prevent eventual relapse with progressive disease (Henderson, 1984; Powles, 1984) .
The biological factors, tumour necrosis factor (TNF) and interferon-y (IFN-y) have been shown to be valuable in transplantable tumour systems but have not yet been tested in primary non-transplantable tumour. TNF is a protein produced in the serum of mice, rats or rabbits when these animals are primed with Bacillus calmette-guerin or Corynebacterium parvum and with bacterial endotoxin, lipopolysaccharide (Carswell et al., 1975; Haranaka et al., 1984) . Macrophages, T cells and tumour cells themselves are also sources of TNF (Mannel et al., 1980; Satomi et al., 1981) . The supernatants of human HL-60 promyelocytic leukaemia cell line also contain TNF (Aggarwal et al., 1985a,b) ; TNF has a multitude of activities in many cells, both normal and transformed cells, in vitro, including a cytotoxic and stimulating activity on different cell lines (Sugarman et al., 1985; Fransen et al., 1986) .
Studies have been carried out using TNF and IFN-y either in combination or individually only on transplanted tumours. These include human tumour xenografts derived from primary breast and bowel tumours and maintained by passage in nude mice (Balkwill et al., 1985 (Balkwill et al., , 1986 , a human transplantable ovarian carcinoma (NIH: OVCAR-3) and murine methylcholanthrene-induced fibrosarcoma in mice (Greasey et al., 1986) . Combined treatment was more effective than individual treatments despite the use of different routes of administration.
The primary in vivo nitrosomethylurea (NMU)-induced rat mammary tumour model is biologically similar to human breast carcinomas (Guillino et al., 1975) . Our extensive studies have shown good correlation between the model and the clinical response in patients and the model is now well established for testing various endocrine agents (Williams et al., 1982; Wilkinson et al., 1986) .
Therefore we decided to study the effect of rHu-TNF and rat-IFN-y administered individually or together using the primary rat mammary tumour model in vivo. The RHu-TNF was produced in E. coli by recombinant DNA technology purified using standard protein purification techniques. The purity is > 99% as determined by SDS polyacrilamide gel electrophoresis. The biological potency of rTNF was determined in the L929 cytotoxicity assay and found to be identical to the natural substance.
The rat IFN-y was purified by the use of immunoabsorbent chromatography using monoclonal antisera derived from Chinese hamster ovary (CHO) cells. The specific activity was 4 x 106 units per mg of pure recombinant rat IFN-y was determined by assaying its protective ability against vesicular stomatitis virus in vitro using a rat cell line.
Concerning checks for endotoxin, the TNF final product contained < 0.1 ng of endotoxin per mg of protein, based on the USP Limulus amoebocyte lysate assay. For the IFN-y, the amounts of endotoxin in the vials (containing 2 x 106 units) assayed by the limulus test revealed amounts below the detection limit.
C) The Macmillan Press Ltd., 1989 Br. J. Cancer (I989), 59, [206] [207] [208] [209] Treatment of tumour-bearing animals The rats commenced the course of treatment when at least one tumour per rat had reached 1.5cm in diameter. The rHu-TNF and rat-IFN-y were assessed together and individually, at doses shown in Table I . In the first study (groups 1-6), rats were randomly allocated to receive a single tail vein injection of rHu-TNF and rat IFN-y either individually or combined and tumour size was monitored over a 28-day period. Control animals received vehicle only, but were otherwise treated identically. In a second study (groups 7-9) with combined rHu-TNF/rat IFN-y treatment, two groups of animals received combined rHu-TNF and IFN-y treatment on day 0: one group received a second injection on day 13.
The animals were exsanguinated either when the tumours ulcerated or on day 28. Serum samples were analysed for oestradiol levels (Dowsett et al., 1987) . In addition, all lesions in the mammary pad areas were removed for oestrogen receptor (ER) determination using the ligand binding assay described previously (McGuire et al., 1973 
Results
Comparison of combined and independent treatments with control group (study 1) An initial study using a lOO1 g rHu-TNF gave rise to two deaths. For this reason we reduced the dose of rHu-TNF to 50pg in the subsequent studies. Table I shows the results of combined and individual treatments with rHu-TNF and rat-IFN-y. The combination of rHu-TNF and rat-IFN-y caused significant (P = 0.004) tumour regression compared to the control group. Conversely treatment with rHu-TNF and rat-IFN-y alone did not cause significant tumour regression (P=0.157 and P=0.40 respectively) when compared with their respective control group (Table I; Figures 1, 2 and 3) . It is interesting, however, that both these agents appeared to cause a reduction in tumour size during the first 4-6 days after administration, before the tumour growth that was observed over the subsequent three weeks (Figures 1 and 2 ).
Repeat dose study (study 2) Animals receiving a single combined dose of rHu-TNF and rat-IFN-y responded in a similar fashion to the animals in study 1, showing highly significant tumour regression at 28 (Ol) were given vehicle only. Each point represents the mean % change in tumour volume from day 0 with 95% confidence interval. % change in tumour volume for treated animals at the end of experiment was statistically different from control animals (P = 0.004). Figure 4 Effect of a single (*) and two doses (U), 13 days apart, of the combined 50gg rHu-TNF and 30,000 units of rat-IFN-y therapy on the growth of NMU-induced rat mammary tumours, compared with controls (El). Each point represents the mean % change in tumour volume from day 0 with 95% confidence interval. % change in tumour volume for each group of treated animals at the end of experiment was statistically different from control group (P= <0.005).
Days
days (P <0.005). Animals receiving a second injection at day 13 showed significantly greater regression than the animals given a single injection (P=0.03) (Table I and Figure 4 ).
Drug toxicity
The only significant toxic effect observed was in animals receiving lOO jig rHu-TNF and 30,000 units rat-IFN-y. Of the 12 animals recovering from this combination, two died within 24h of injection and the remaining 10 showed weight loss, with bleeding from eyes, nose and rectum; recovering from the latter symptoms took 3-4 days, while body weight was normal within two weeks. We have measured ER in 41 tumours. Seven out of 10 control animals had ER positive tumours (mean 93, range <10-441fmolmg-1) compared to 9/11 animals receiving rHu-TNF (mean 85.4, range <10-222fmolmg-1) and 5/8 animals receiving rat-IFN-y (mean 42.2, range <10-75fmolmg-1). Ten out of 12 animals who received combined therapy had ER positive tumours (mean 62.8, range <10-136fmolmg-1). There was no significant difference between the control and treated groups.
Discussion
This study demonstrates, for the first time, the synergistic effect of rHu-TNF and IFN-y in carcinogen-induced primary rat mammary tumours. We felt it important to evaluate these agents in this primary tumour model since (a) we have demonstrated the close similarity of this model with human hormone-sensitive breast cancer, (b) we feel that transplantable models are not suitable for evaluating agents that may work by affecting components of the immune system and (c) we are particularly interested in studying the effects of these compounds in association with endocrine agents and this model is the principal system for evaluating new endocrine agents for the treatment of human breast cancer. Our study confirms the findings of Balkwill et al. (1986) in that the combination of the two drugs was potent in causing tumour regression whilst individually they are ineffective.
The mechanism of the synergism of TNF with IFN-y remains obscure. Other agents such as actinomycin D also enhance TNF cytotoxicity in vitro and it may be that both this and IFN-y inhibit some repair mechanism. A more likely possibility is that IFN-y induces the synthesis of TNF receptor thus enhancing TNF cytotoxicity (Aggarwal et al., 1985a, b) but some reports do not concur with either this possibility or that IFN-y increases the affinity of TNF for the receptor (Salwiz & Lippman, 1986) .
Concerning the effect of these peptides on steroid receptor binding and synthesis, some reports suggest that IFN-y potentiates the effect of endocrine agents in vitro (Iacobelli et al., 1986; , while others suggest that IFNy increases oestrogen receptor content (lacobelli et al., 1986; Van Den Berg et al., 1986) . Our study indicates that, in vivo, there is little, if any, effect of the agents on ER content, although IFN-y-treated animals had tumours with marginally lower ER than controls.
Further studies are needed to define precisely the interaction of these peptides on steroid and growth factorinduced proliferation of breast cancer cells in vivo and in vitro. Studies by our group (Travers et al., 1988) have demonstrated that in breast carcinomas several contain growth factors and it is known that TNF can inhibit growth factor effects in vitro (Sugarman et al., 1987) .
We intend to initiate clinical studies designed to determine their mechanism of action and exact scheduling with other therapies for breast cancer.
